Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2
different doses compared to Metformin or to Sitagliptin given for 78 weeks in different
modalities of treatment in patients with type 2 diabetes mellitus.